In prostate cancer and breast cancer with high expression of BRF2, pan-active BCL-2 protein family antagonist (Sabutoclax) inhibits tumor progression by promoting cell apoptosis [27, 28]. The gene discussed is BCL2; the disease is prostate carcinoma.